Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$7.36 - $11.17 $41,952 - $63,669
5,700 Added 570.0%
6,700 $73,000
Q3 2022

Nov 07, 2022

SELL
$7.86 - $11.71 $68,051 - $101,385
-8,658 Reduced 89.65%
1,000 $8,000
Q2 2022

Aug 09, 2022

BUY
$7.06 - $25.52 $68,185 - $246,472
9,658 New
9,658 $76,000
Q1 2022

May 16, 2022

SELL
$23.34 - $36.08 $305,847 - $472,792
-13,104 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$17.63 - $37.1 $231,023 - $486,158
13,104 New
13,104 $448,000
Q2 2021

Aug 12, 2021

SELL
$25.57 - $44.88 $24,393 - $42,815
-954 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$19.02 - $31.15 $18,145 - $29,717
954 New
954 $24,000
Q4 2020

Feb 12, 2021

SELL
$18.49 - $25.13 $5,546 - $7,539
-300 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$15.19 - $22.4 $4,557 - $6,720
300 New
300 $5,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.